About AVT
Browse Articles
Customer Services

Current Issue

Displaying 11 results:


Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAt substudy

Esther Merlini, Laura Galli, Camilla Tincati, Elvira S Cannizzo, Andrea Galli, Nicola Gianotti, Giuseppe Ancona, Camilla Muccini, Antonella d’Arminio Monforte, Giulia Marchetti, Antonella Castagna, the MODAt study group

Antiviral Therapy 2018; 23:633-637

Short communication

Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: the TAF-IR Study

Christoph D Spinner, Sebastian Schulz, Ulrike Bauer, Jochen Schneider, Johanna Bobardt, Alexander Von Werder, Roland M Schmid, Alexander Zink, Eva Wolf, Roman Iakoubov

Antiviral Therapy 2018; 23:629-632

Short communication

Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone

Peter L Havens, Dustin Long, Gertrud U Schuster, Catherine M Gordon, Georgine Price, Craig M Wilson, Bill G Kapogiannis, Kathleen Mulligan, Charles B Stephensen, the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 117 and 109 study teams

Antiviral Therapy 2018; 23:623-628

Short communication

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

Jae-Hoon Ko, Hyeri Seok, Sun Young Cho, Young Eun Ha, Jin Yang Baek, So Hyun Kim, Yae-Jean Kim, Jin Kyeong Park, Chi Ryang Chung, Eun-Suk Kang, Duck Cho, Marcel A Müller, Christian Drosten, Cheol-In Kang, Doo Ryeon Chung, Jae-Hoon Song, Kyong Ran Peck

Antiviral Therapy 2018; 23:617-622

Short communication

Hesperidin attenuates influenza A virus (H1N1) induced lung injury in rats through its anti-inflammatory effect

Zhen Ding, Gengyun Sun, Zhongming Zhu

Antiviral Therapy 2018; 23:611-615

Short communication

HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era

Carmine Minichini, Mario Starace, Stefania De Pascalis, Margherita Macera, Laura Occhiello, Mara Caroprese, Martina Vitrone, Vincenzo Iovinella, Barbara Guerrera, Mario Masarone, Nicola Coppola

Antiviral Therapy 2018; 23:605-609

Original article

Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection

Frederick Lahser, Angela Galloway, Peggy Hwang, John Palcza, Joann Brunhofer, Janice Wahl, Michael Robertson, Eliav Barr, Todd Black, Ernest Asante-Appiah, Barbara Haber

Antiviral Therapy 2018; 23:593-603

Original article

Comparative effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens for HCV infection

Rohit P Ojha, Brooke R MacDonald, Tzu-Chun Chu, Esther O Fasanmi, Jonathan D Moore, Rachel A Stewart

Antiviral Therapy 2018; 23:585-592

Original article

RIG-I enhances interferon-α response by promoting antiviral protein expression in patients with chronic hepatitis B

Shu Wu, Jinpiao Lin, Ya Fu, Qishui Ou

Antiviral Therapy 2018; 23:575-583

Original article

Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-α-2a treatment in child patients

Juncheng Yang, Guifeng Yang, Haitang He, Lu Ning, Zhihua Liu, Qunfang Fu, Haitao Chen, Haohui Deng, Zhanhui Wang, Kangxian Luo

Antiviral Therapy 2018; 23:567-574

Copyright © Nucleus Global 2019. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.